Pfizer to acquire pair of meningitis vaccines from GSK
NEW YORK — Pfizer Inc. plans to buy GlaxoSmithKline’s quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for about $130 million. (NYSE: PFE) today announced that it has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130 million (€115 million). Pfizer